Skip to content

Geron GERN Business Segments — Total revenues

Similar metrics at other companies

Vir Biotechnology, Inc. logo
VIRReportable Segment — Total revenues
-$29K-101%
BioCryst Pharmaceuticals logo
BCRXReportable Segment — Total revenues
$156.41M+7.5%
Arcus Biosciences logo
RCUSReportable segment — Total revenues
$17M-39.3%
EverCommerce Inc. logo
EVCMReportable Segment — Total revenues
$147.47M+3.6%
Omnicell logo
OMCLReportable Segment — Total revenues
$309.88M+14.9%
Open Text logo
OTEXReportable Segment — Total revenues
$1.28B+2.2%

Other financials

Income statement

See full
Revenue$51.8M+30.9%
Operating income$158.0K+101%
Net income-$3.6M+81.6%
EPS (diluted)-$0.01+66.7%

Balance sheet

See full
Cash & equivalents$48.7M-12.2%
Total debt$134.0M+10.0%
Total equity$229.1M-14.6%
Total assets$534.1M-5.0%

Cash flow

See full
Operating cash flow-$62.9M-31.1%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$888.51M-7.6%
Enterprise value$973.78M-5.3%
P/S4.7×-174×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-27.1%-7.8pp
Debt / equity0.6×+0.1×
Current ratio6.8×-1.1×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Geron’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Geron's business segments — total revenues.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Geron's business segments — total revenues?
Geron (GERN) reported business segments — total revenues of $51.8M in Q1 2026.
How has Geron's business segments — total revenues changed year-over-year?
Geron's business segments — total revenues increased by 30.8% year-over-year, from $39.6M to $51.8M.
What does business segments — total revenues mean?
Represents the total gross income generated by the specific business segment through its primary operations, including collaboration agreements, licensing, and milestone payments. This metric serves as a key indicator of the segment's commercial traction and its ability to monetize intellectual property or clinical development progress.